July 26, 2016



## Rigel Announces Conference Call and Webcast to Report Second Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., July 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2016 financial results after market close on Tuesday, August 2, 2016. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results.

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 54498109. The conference call will also be webcast live and can be accessed from Rigel's website at <u>www.rigel.com</u>. The webcast will be archived and available for replay after the call via the Rigel website.

## About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for lgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Ryan Maynard Phone: 650.624.1284 Email: <u>invrel@rigel.com</u>

Media Contact: Susan C. Rogers, Rivily, Inc. Phone: 650.430.3777 Email: <u>susan@rivily.com</u>

Logo - https://photos.prnewswire.com/prnh/20030226/RIGLLOGO

To view the original version on PR Newswire, visit<u>http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2016-financial-results-300303623.html</u>

SOURCE Rigel Pharmaceuticals, Inc.